Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 5/20 | 0.52 |
| ▸ | GSK3B | P49841 | 5/20 | 0.52 |
| ▸ | CDK4 | P11802 | 3/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | IKBKB | O14920 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9957490 | 0.86 | KDM4E (0.51) | KDM4ECDK2GSK3BCDK4DYRK1A | |
| SCHEMBL9957233 | 0.85 | CDK2 (0.50) | KDM4ECDK2GSK3BCDK4DYRK1A | |
| SCHEMBL9956478 | 0.77 | CDK4 (0.53) | KDM4ECDK2GSK3BCDK4DYRK1A | |
| SCHEMBL28794435 | 0.76 | GSK3B (0.58) | CDK2GSK3BCDK4DYRK1AMEN1 | |
| SCHEMBL867999 | 0.71 | KCNH2 (0.58) | CDK2GSK3BCDK4DYRK1AMEN1 | |
| SCHEMBL3697392 | 0.71 | KCNH2 (0.58) | KDM4ECDK2GSK3BCDK4DYRK1A | |
| SCHEMBL14378915 | 0.69 | CDK2 (0.66) | CDK2GSK3BCDK4DYRK1AMEN1 | |
| SCHEMBL9957787 | 0.69 | PIK3C3 (0.61) | CDK2GSK3BCDK4DYRK1AMEN1 | |
| SCHEMBL3702737 | 0.68 | SYK (0.56) | KDM4ECDK4MEN1KMT2AKCNH2 | |
| SCHEMBL4486744 | 0.68 | CDK2 (1.00) | CDK2GSK3BCDK4DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655340-B1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| EP-2655340-B1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| US-8901147-B2 | Bi-heteroaryl compounds as Vps34 inhibitors | NOVARTIS AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-8901147-B2 | Bi-heteroaryl compounds as Vps34 inhibitors | NOVARTIS AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-8901147-B2 | Bi-heteroaryl compounds as Vps34 inhibitors | NOVARTIS AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| US-20130338159-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| EP-2655340-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | Novartis AG (CH) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085815-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085815-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | VPS35, VPS26B, VPS26A | KDM4E 1589/4885CDK2 2400/4885GSK3B 912/4885 |
| US-20130338159-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | VPS35, VPS26B, VPS26A | KDM4E 1638/4885CDK2 2365/4885GSK3B 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.